Recent media reports on Plavix® may be misinterpreted by patients with coronary stents and other conditions*, causing these patients to inappropriately stop taking the anti-clotting drug clopidogrel (Plavix®).
In any case, patients taking Plavix® for any reason must discuss the benefits and risks of anti-clotting medication with their health care provider and should not stop Plavix® on their own.
Patients should be warned that discontinuation of Plavix® in patients with recently-placed stents can cause clot formation within the stent that could result to serious harm or death.
*According to the 2006 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention (PCI), Class I recommendations indicate the use of aspirin and clopidigrel in patients undergoing angioplasty with stent implantation (contraindications include aspirin resistance, allergy or risk of bleeding).
Source: PharmaLive
.jpg)
» Patent Case Settlement on Plavix® from ThePharmVoice
The makers of Plavix®, Sanofi-Aventis and Bristol-Myers Squibb have tentatively settled a patent dispute on the drug. Plavix®, an anti-clotting agent is the world’s second-best selling drug have been settled to be generically manufactured... [Read More]
Tracked on: March 23, 2006 2:49 AM | Permalink to Trackback